A recent pooled study by Smith JA et al. (2021) investigated cough frequency in chronic cough patients treated with gefapixant. “In this pooled analysis, gefapixant 45 mg BID demonstrated significant reductions in 24-hour and awake cough frequency vs placebo, with no increase in serious AEs”.
The VitaloJAK™ was used to measure objective cough frequency in this study. Vitalograph’s expert team of cough analysts and the highly consistent performance of the VitaloJAK continue to provide industry-leading objective cough data across different disease areas.